Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study

Annals of Internal Medicine

Volumn 116, Issue 4, 1992, Pages 273-278

  Saikku, Pekka ^a   Leinonen, Maija ^b   Tenkanen, Leena ^c   Linnanmäki, Eila ^a   Ekman, Marja Riitta ^a   Manninen, Vesa ^d   Mänttäri, Matti ^d   Frick, M Heikki ^d   Huttunen, Jussi K ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; BACTERIUM LIPOPOLYSACCHARIDE; GEMFIBROZIL; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHLAMYDIACEAE; CHLAMYDIASIS; CONTROLLED STUDY; CORONARY RISK; ENZYME IMMUNOASSAY; FEMALE; HEART INFARCTION; HUMAN; IMMUNOFLUORESCENCE TEST; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SUDDEN DEATH;

ADULT; ANTIBODIES, BACTERIAL; ANTIGEN-ANTIBODY COMPLEX; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; CORONARY DISEASE; HUMAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGE; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0026595043     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-116-4-273     Document Type: Article

References (36)

1. Grayston JT, Kuo CC, Campbell LA, Wang SP. Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int J Syst Bacteriol. 1989;39:88-90.
2. Grayston JT, Campbell LA, Kuo CC, Mordhorst CH, Saikku P, Thom DH, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis. 1990;161:618-25.
3. Saikku P, Wang SP, Kleemola M, Brander E, Rusanen E, Grayston JT. An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis. 1985;151:832-9.
4. Kleemola M, Saikku P, Visakorpi R, Wang SP, Grayston JT. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. J Infect Dis. 1988;157:230-6.
5. Mordhorst CH, Wang SP, Myhra W, Grayston JT. Chlamydia pneumoniae, strain TWAR, infections in Denmark 1975-1987. In: Bowie WR, Caldwell HD, Jones RP, Mårdh PA, Ridgway GL, Schachter J, et al.; eds. Chlamydial Infections. Cambridge:Cambridge University Press; 1990:418-21.
6. Mårdh PA, Paavonen J, Puolakkainen M. Chlamydia. New York: Plenum Medical Book Company; 1989.
7. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983-6.
8. Leinonen M, Linnanmäki E, Mattila K, Nieminen MS, Valtonen V, Leirisalo-Repo M, et al. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog. 1990;9:67-73.
9. Thorn DH, Wang SP, Grayston JT, Siscovick DS, Stewart DK, Kronmal RA, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb. 1991;11:547-51.
10. Lopes-Virella M, Virella G. Immunological and microbial factors in the pathogenesis of atherosclerosis. Clin Immunol Immunopathol. 1985;37:377-86.
11. Manninen V, Wood C; eds. Helsinki Mean Study: a controlled coronary prevention trial. Design and baseline findings. Eur Heart J. 1987;8:(Suppl 1)1-43.
12. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45.
13. Huttunen JK, Manninen V, Tenkanen L, Heinonen OP, Koskinen P, Frick MH. Drug-induced changes in HDL cholesterol and coronary heart disease. Experiences from the Helsinki Heart Study. In: Miller NE; ed. High Density Lipoproteins and Atherosclerosis. Amsterdam: Elsevier Science Publishers; 1989:191-8.
14. Manninen V, Huttunen JK, Tenkanen L, Heinonen OP, Mänttärim, Frick MH. High density lipoprotein cholesterol as a risk factor for coronary heart disease in the Helsinki Heart Study. In: Miller NE; ed. High Density Lipoproteins and Atherosclerosis. Amsterdam: Elsevier Science Publishers; 1989:35-42.
15. Wang SP, Grayston JT. Microimmunofluorescence serological studies with the TWAR organism. In: Oriel JD, Ridgway G, Schachter J, Taylor-Robinson D, Ward M; eds. Chlamydial Infections. Cambridge: Cambridge University Press; 1986;329-32.
16. Breslow NE, Day NE. Statistical Methods in Cancer Research. Vol. 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980:192-246.
17. Granfors K. Measurement of immunoglobulin M (IgM), IgG and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunosorbent assay: persistence of serum antibodies during disease. J Clin Microbiol. 1979;9:336-41.
18. Höiby N, Doring G. Immunoglobulin responses and immune complex formation in chronic lung diseases. Clin Microbiol Newsletter. 1988;9:133-6.
19. Brett MM, Ghoneim AT, Littlewood JM. Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child. 1990;65:259-63.
20. Sarov I, Sarov B, Lunefeld E, Hagai Z, Chaim W, Figura B. The significance of chlamydia-specific serum IgA antibodies in Chlamydia trachomatis infections. 1st Proc Eur Soc Chlamydia Res. Stockholm: Almqvist & Wiksell International; 1988:234-8.
21. Chaim W, Sarov B, Sarov I, Piura B, Cohen A, Insler V. Serum IgG and IgA antibodies to chlamydia in ectopic pregnancies. Contraception. 1989;40:59-71.
22. Höjby N, Döring G, Schiötz PO. The role of immune complexes in the pathogenesis of bacterial infections. Ann Rev Microbiol. 1986; 40:29-53.
23. Lahesmaa-Rantala R, Granfors K, Kekomäki R, Toivanen A. Circulating yersinia specific immune complexes after acute yersiniosis; a follow-up study of patients with and without arthritis. Ann Rheum Dis. 1987;46:121-6.
24. Puolakkainen M, Linnanmäki E, Paavonen J, Leinonen M, Saikku P. Chlamydial lipopolysaccharide containing circulating immune complexes in pelvic inflammatory disease. In: Bowie WR, Caldwell HD, Jones RP, Mårdh PA, Ridgway GL, Schachter J, et al.; eds. Chlamydial Infections. Cambridge: Cambridge University Press; 1990: 319-22.
25. Puolakkainen M, Ukkonen P, Saikku P. Seroepidemiology of chlamydia in Finland 1971-1987 by complement fixation test. Epidemiol Infect. 1989;102:287-95.
26. Black CM, Perez R. Chlamydia pneumoniae multiplies within human pulmonary macrophages. In: Abstracts of the 90th Annual Meeting of the American Society for Microbiology. Washington, DC: American Society for Microbiology. 1990:80.
27. Van Lenten BJ, Fogelman AM, Haberland ME, Edwards PA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci USA. 1986;83:2704-8.
28. Brade H, Brade L, Nano FE. Chemical and serological investigations on the genus-specific lipopolysaccharide epitope of Chlamydia. Proc Natl Acad Sci USA. 1987;84:2508-12.
29. Nurminen ME, Rietschel ET, Brade H. Chemical characterization of Chlamydia trachomatis lipopolysaccharide. Infect Immun. 1985;48: 573-5.
30. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Eng J Med. 1989;320:915-24.
31. Klimov AV, Denisenko AD, Popov AV, Nagorne VA, Pleskov VM, Vinogradov AG, et al. Lipoprotein-antibody immune complexes. Their catabolism and role in foam cell formation. Atherosclerosis. 1985;58:1-15.
32. Griffith RL, Virella GT, Stevenson HC, Lopes-Virella MF. Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J Exp Med. 1988;168:1041-59.
33. Williams DM, Bonewald LF, Roodman GD, Byrne GI, Magee DM, Schachter J. Tumor necrosis factor alpha is a cytotoxin induced by murine Chlamydia trachomatis infection. Infect Immun. 1989;57: 1351-5.
34. Williams DM, Magee DM, Bonewald LF, Smith JG, Bleicker CA, Byrne GI, et al. A role in vivo of tumor necrosis factor alpha in-host defense against Chlamydia trachomatis. Infect Immun. 1990;58: 1572-6.
35. Shemer-Avni Y, Holtmann H, Wallach D, Sarov I. Cytokine-cell interactions resulting in Chlamydia trachomatis inhibition - mechanisms involved. In: Bowie WR, Caldwell HD, Jones RP, Mårdh PA, Ridgway GL, Schachter J, et al.; eds. Chlamydial Infections. Cambridge: Cambridge University Press; 1990:173-6.
36. Kawakami M, Pekala PH, Lance MD, Cerami A. Lipoprotein lipase suppression in 3T3 L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA. 1983;79:912-6.